Generic Name and Formulations:
Gatifloxacin 0.3%; oph soln; contains benzalkonium chloride.
Indications for ZYMAR:
Susceptible bacterial conjunctivitis.
Adults and Children:
1 drop every 2hrs while awake (max 8 times/day) on days 1 and 2, then 1 drop up to 4 times/day while awake on days 3–7.
Risk of corneal endothelial cell injury: do not administer into anterior chamber of the eye. Discontinue if superinfection or hypersensitivity occurs. Remove contact lenses. Pregnancy. Nursing mothers.
Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival hemorrhage, dry or red eye, eye discharge or pain, eyelid edema, headache, reduced visual acuity, taste disturbance.
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure